DaVita (NYSE:DVA) Sets New 1-Year High – Time to Buy?

DaVita Inc. (NYSE:DVA)’s stock price reached a new 52-week high on Thursday . The company traded as high as $203.54 and last traded at $202.8560, with a volume of 208617 shares changing hands. The stock had previously closed at $198.54.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on DVA shares. TD Cowen raised their price target on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Truist Financial boosted their target price on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and upped their price target for the stock from $126.00 to $220.00 in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $199.17.

DaVita Stock Up 2.2%

The firm has a 50 day moving average of $176.13 and a two-hundred day moving average of $146.09. The firm has a market capitalization of $13.37 billion, a price-to-earnings ratio of 19.32, a price-to-earnings-growth ratio of 0.67 and a beta of 0.91.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the previous year, the firm earned $2.00 earnings per share. The business’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Todd Asset Management LLC acquired a new stake in shares of DaVita during the third quarter valued at about $21,842,000. Doma Perpetual Capital Management LLC increased its stake in shares of DaVita by 23.3% in the third quarter. Doma Perpetual Capital Management LLC now owns 355,574 shares of the company’s stock valued at $47,245,000 after buying an additional 67,214 shares during the period. Intech Investment Management LLC raised its holdings in DaVita by 122.4% in the 3rd quarter. Intech Investment Management LLC now owns 27,441 shares of the company’s stock valued at $3,646,000 after buying an additional 15,104 shares during the last quarter. Nordea Investment Management AB boosted its position in DaVita by 18.0% during the 4th quarter. Nordea Investment Management AB now owns 338,192 shares of the company’s stock worth $38,321,000 after buying an additional 51,607 shares during the period. Finally, Munich Reinsurance Co Stock Corp in Munich acquired a new stake in DaVita during the 3rd quarter worth approximately $5,419,000. 90.12% of the stock is currently owned by institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.